On May 17, 2024, Health Canada published the Interim Order Concerning the Sale of Certain Natural Health Products Containing Ephedrine or Pseudoephedrine. This order introduces specific condition-of-sale regulations for natural […] Read More >>
Health Canada continues its commitment to updating and revising its monographs, releasing Batch 3 for consultation. This represents another crucial step in ensuring the accuracy and applicability of information provided […] Read More >>
On April 24, 2024, Health Canada published amendments to the Cosmetics Regulations in Canada. These amendments, detailed in the Cosmetic Regulations under the Food and Drugs Act, signify important changes […] Read More >>
On May 12, 2023, Health Canada alerted industry of a proposal to introduce cost recovery fees for Natural Health Products (NHPs). This proposal, initially released for consultation from May 12 […] Read More >>
In Canada, infant formulas and human milk fortifiers are regulated under the Food and Drug Regulations, Part B, Division 25 (B.25.019). Health Canada defines infant foods as food to be […] Read More >>
Health Canada’s ongoing efforts to update and revise its monographs continue with the release of Batch 2 for consultation. This marks another significant step in ensuring the accuracy and relevance […] Read More >>
The Canadian Food and Drug Regulations (FDR) have established regulations for Food for Special Dietary use (FSDU) as well as food for infants, covered under Divisions 24 and 25 of […] Read More >>
The Canadian Food and Drug Regulations (FDR) have previously set over 300 composition standards for food products being imported and traded within and between provinces of Canada. These compositional standards […] Read More >>
Health Canada’s Natural Non-Prescription Health Products Directorate (NNHPD) recently announced that beginning at the end of October, they will begin consulting on monograph revisions. This initiative is geared toward enhancing […] Read More >>
Attention all manufacturers, packagers, distributors, and sellers of Ready-to-Eat (RTE) foods in Canada, as of October 1, 2023, Health Canada’s updated policy on Listeria monocytogenes in RTE foods is now […] Read More >>
On Thursday, September 21, 2023, representatives from dicentra attended the CHFA Now’s Regulatory Forum in Toronto in order to stay informed and be able to provide our clients, prospects, and […] Read More >>
In the ever-evolving landscape of regulatory compliance for the natural health product (NHP) industry in Canada, recent developments such as Bill C-47 (refresher here) and the NHP GMP Inspection Program […] Read More >>
On June 22, 2023, Bill C-47 received Royal Assent, introducing amendments to the Food and Drugs Act (FDA) concerning Natural Health Products (NHPs). These amendments extend the enforcement power of […] Read More >>
Definition of a Pregnancy Test A urine pregnancy test device is an In-Vitro Diagnostic (IVD) hormonal assay that measures the beta (β) subunit of Human Chorionic Gonadotrophin (hCG) levels in […] Read More >>
On May 12, 2023, Health Canada alerted industry of a new proposal to introduce cost recovery fees for Natural Health Product (NHP) regulatory activities in Canada. The proposal, open for […] Read More >>
As of March 21, 2023, the Natural and Non-prescription Health Product Directorate (NNHPD) began applying new refusal criteria against Site Licence (SL) and Foreign Site Reference Number (FSRN) submissions, as […] Read More >>
On March 27, 2023, Health Canada updated the “Policy on Listeria monocytogenes in Ready-to-Eat Foods”. This new policy will come into effect on October 1, 2023. Until then, the 2011 […] Read More >>
The ALR application due date for MDELs is April 1, 2023. If you hold a Medical Device Establishment Licence (MDEL), you must submit your completed ALR application before April 1. […] Read More >>
On December 22, 2022, Health Canada opened consultation on a proposal to amend the Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs). The […] Read More >>
On December 16, 2022, Health Canada issued a notice to stakeholders regarding their proposal to amend the regulations for Biologic Drugs (Schedule D drugs) in Division 4, Part C, of […] Read More >>